Next-generation sequencing (NGS) enables researchers to better understand the biology that drives cancer predisposition and proliferation. These insights can support the development of targeted therapeutics and multi-analyte tumor analysis. NGS also opens the door for discovery of novel methods to monitor cancer treatment and recurrence.
lllumina brings innovation to cancer drug development by offering comprehensive genomic solutions working in collaboration with leading pharmaceutical providers.
As targeted therapies make their way through pharmaceutical pipelines, the need for comprehensive tumor profiling is increasing.Learn More
NGS helps drug developers to explore genomic variation. This informs target discovery, validation, and clinical development.Learn More